Supplementary Tables S2-S12 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy

<p>Supplementary Table S2. Patient characteristics and number of cells analyzed. Supplementary Table S3. Marker genes for each cluster Supplementary Table S4. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between response groups. Supplementary Table S5. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between metastatic sites. Supplementary Table S6. Top 50 Marker genes for each lymphoid cluster Supplementary Table S7. Genes used for pathway signatures retrieved from MSigDB. Supplementary Table S8. Genes differentially expressed between lymphoid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S9. Top 50 Marker genes for each myeloid cluster Supplementary Table S10. Genes differentially expressed between myeloid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S11. Genes differentially expressed between myeloid clusters 1, 5, and 7. Supplementary Table S12. Genes used for survival analyses. Genes were selected by using a max pvalue cutoff of 0.05.</p>

Duke Scholars

Author Donald Patrick McDonnell Pharmacology & Cancer Biology

Author Ching-yi Chang Pharmacology & Cancer Biology

Author Binita Chakraborty  

Author Kent James Weinhold Surgery, Surgical Sciences